Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging borders in HIV care education: Lessons from an online multidisciplinary international exchange programme.

HIV medicine·2025
Same author

Clinical Management of Hospitalized Patients With High-Consequence Infectious Diseases in England.

Health security·2024
Same author

Long versus short course anti-microbial therapy of uncomplicated Staphylococcus aureus bacteraemia: a systematic review.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2024
Same author

Exploring young people's attitudes to HIV prevention medication (PrEP) in England: a qualitative study.

BMJ open·2024
Same author

Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.

NEJM evidence·2024
Same author

Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis.

BMC infectious diseases·2023
Same journal

Rheumatoid arthritis: previously untreated early disease.

BMJ clinical evidence·2016
Same journal

Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.

BMJ clinical evidence·2016
Same journal

Subarachnoid haemorrhage (spontaneous aneurysmal).

BMJ clinical evidence·2016
Same journal

Malaria: fluid therapy in severe disease.

BMJ clinical evidence·2016
Same journal

Age-related macular degeneration: anti-vascular endothelial growth factor treatment.

BMJ clinical evidence·2016
Same journal

MRSA: treating people with infection.

BMJ clinical evidence·2016
See all related articles

Related Experiment Video

Updated: May 31, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

HIV: treating tuberculosis.

Brendan Payne1, Richard Bellamy

  • 1Department of Infection and Travel Medicine, James Cook University Hospital, Middlesbrough, UK.

BMJ Clinical Evidence
|July 6, 2011
PubMed
Summary
This summary is machine-generated.

HIV-positive individuals with tuberculosis face a high risk of active disease and relapse. This systematic review evaluates various first- and second-line treatments to improve outcomes for these patients.

Related Experiment Videos

Last Updated: May 31, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Area of Science:

  • Infectious Diseases
  • Public Health
  • Clinical Medicine

Background:

  • Individuals co-infected with HIV and Mycobacterium tuberculosis have a significantly higher annual risk (5%-10%) of developing active tuberculosis compared to HIV-negative individuals.
  • Untreated tuberculosis in people with HIV is associated with high mortality rates.
  • Over 5% of individuals with HIV and tuberculosis experience relapse even after successful treatment.

Purpose of the Study:

  • To systematically review and evaluate the effectiveness and safety of first-line and second-line treatments for tuberculosis in HIV-positive individuals.
  • To answer key clinical questions regarding optimal therapeutic strategies for this vulnerable population.

Main Methods:

  • Conducted a systematic review of medical literature, including Medline, Embase, and The Cochrane Library, up to July 2009.
  • Included data from systematic reviews, randomized controlled trials (RCTs), and observational studies.
  • Incorporated harms alerts from regulatory agencies like the US FDA and UK MHRA.

Main Results:

  • Identified 23 relevant systematic reviews, RCTs, or observational studies meeting inclusion criteria.
  • Performed a GRADE evaluation to assess the quality of evidence for various interventions.
  • Analyzed a range of interventions including immunotherapy, antimycobacterial combinations, conventional antituberculous treatments, directly observed therapy, and highly active antiretroviral treatment.

Conclusions:

  • Presents information on the effectiveness and safety of multiple interventions for tuberculosis in HIV-positive individuals.
  • Key interventions reviewed include adjuvant immunotherapy, various antimycobacterial treatment combinations, conventional antituberculous therapies, directly observed therapy, and highly active antiretroviral treatment.
  • Findings inform treatment decisions for co-infected patients, addressing both efficacy and safety profiles of different therapeutic approaches.